FFFarinaz Forouzannia

Farinaz Forouzannia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Farinaz Forouzannia has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of sustained virologic response on liver-related mortality among individuals living with hepatitis C by treatment era: A population-based retrospective cohort study

    by Aysegul Erman, Karl Everett, William W. L. Wong, Farinaz Forouzannia, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, Beate Sander

    Purpose: Sustained virologic response (SVR) is a validated surrogate marker for successful hepatitis C virus (HCV) treatment. Historically, interferon-based therapies, the standard of care for decades, offered only limited efficacy with respect to SVR. The recent introduction of highly effective direct-acting antivirals (DAAs) revolutionised treatment, expanding treatment eligibility among individuals with advanced liver disease (ALD) and drug/alcohol-related substance use disorder. Given these clinical policy shifts, we assessed the real-world impact of SVR on liver-related death for these key clinical groups for whom treatment had previously been less feasible. Methods: We conducted a population-based, cohort study of Ontario residents with HCV viremia between January 1st, 1999, and December 31st, 2018, with follow-up to May 31st, 2021 (N = 73,411) and used cause-specific hazard models to explore the association between SVR and liver-related death. Results: SVR was associated with a significant reduction in liver-related deaths (adjusted hazard ratio [aHR]: 0.22, 95%CI: 0.20–0.24). This benefit was consistent across all levels of liver disease severity, including individuals with (aHR: 0.11, 95%CI: 0.06–0.18) and without (aHR: 0.13, 95%CI: 0.10–0.17) cirrhosis, individuals with ALD (aHR: 0.24, 95%CI: 0.22–0.27) as well as among individuals with (aHR: 0.24, 95%CI: 0.21–0.27) and without (aHR: 0.21, 95%CI: 0.18–0.24) substance use disorder. Conclusions: This study demonstrates the real-world impact of SVR on liver-related mortality and highlights the value of early treatment and continued support for populations who are marginalised.


  • Open Access

    Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development

    by Julien Smith-Roberge, Farinaz Forouzannia, Abdullah Hamadeh, Zeny Feng, Nashira Popovic, William W L Wong

    Background: Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the global strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades. Objective: This study develops a framework to estimate the prevalence of CHB and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021. Methods: We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of CHB, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada. Results: We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI 0.443%-0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI 50.9%-58.9%). Conclusions: The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data.


  • Open Access

    Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development (Preprint)

    by Julien Smith-Roberge, Farinaz Forouzannia, Abdullah Hamadeh, Zeny Feng, Nashira Popovic, William W L Wong

    BACKGROUND Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the Global Strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades. OBJECTIVE This study develops a framework to estimate the prevalence of chronic hepatitis B and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021. METHODS We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of chronic hepatitis B, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada. RESULTS We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI: 0.443% - 0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI: 50.9% - 58.9%). CONCLUSIONS The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data. CLINICALTRIAL

  • Open Access

    Feasibility of hepatitis C elimination by screening and treatment alone in high-income countries

    by Feng Tian, Farinaz Forouzannia, Zeny Feng, Mia J. Biondi, Andrew B. Mendlowitz, Jordan J. Feld, Beate Sander, William W. L. Wong

    Background & Aims: Despite the availability of highly effective direct-acting antiviral therapy, chronic hepatitis C (CHC) continues to cause a major public health burden. In many high-income countries, treatment rates have been declining, which was exacerbated by the impact of the COVID-19 pandemic, threatening the ability to meet the World Health Organization (WHO)’s targets for eliminating hepatitis C virus (HCV) as a public health threat by 2030. We sought to model the impact of CHC in Canada, a resource-rich country with ongoing immigration from HCV-endemic regions; which relies exclusively on risk-based screening for case identification. Approach & Results: We developed an agent-based model to characterize the HCV epidemic in a high-income country with ongoing immigration. Combinations of prevention such as harm-reduction, screening, and treatment strategies were considered. Model parameters were estimated from the literature and calibrated against historical HCV data. Sensitivity analyses were performed to assess uncertainty. Under the current status quo of risk-based screening, we predict the incidence of CHC-induced decompensated cirrhosis, hepatocellular carcinoma, and liver-related deaths would decrease by 79.4%, 76.1%, and 62.1%, respectively, between 2015–2030, but CHC incidence would only decrease by 11.1%. Results were sensitive to HCV transmission rate and annual number of people initiating treatment. Conclusions: Current risk-based screening, and subsequent treatment, will be inadequate to achieve WHO goals. With extensive scale-up in screening, and treatment, the mortality target may be achievable, but the target for preventing new CHC cases is unlikely reachable, highlighting the importance of developing enhanced harm-reduction strategies for HCV elimination. Export


  • Open Access

    Impact of new direct‐acting antiviral therapy on the prevalence and undiagnosed proportion of chronic hepatitis C infection

    by Farinaz Forouzannia, Abdullah Hamadeh, Ana Maria Passos‐Castilho, Aysegul Erman, Amanda Yu, Zeny Feng, Naveed Z. Janjua, Beate Sander, Christina Greenaway, William W. L. Wong

    Background: Patients with chronic hepatitis C (CHC) can be cured with the new highly effective interferon‐free combination treatments (DAA) that were approved in 2014. However, CHC is a largely silent disease, and many individuals are unaware of their infections until the late stages of the disease. The impact of wider access to effective treatments and improved awareness of the disease on the number of infections and the number of patients who remain undiagnosed is not known in Canada. Such evidence can guide the development of strategies and interventions to reduce the burden of CHC and meet World Health Organization's (WHO) 2030 elimination targets. The purpose of this study is to use a back‐calculation framework informed by provincial population‐level health administrative data to estimate the prevalence of CHC and the proportion of cases that remain undiagnosed in the three most populated provinces in Canada: British Columbia (BC), Ontario and Quebec.Methods: We have conducted a population‐based retrospective analysis of health administrative data for the three provinces to generate the annual incidence of newly diagnosed CHC cases, decompensated cirrhosis (DC), hepatocellular carcinoma (HCC) and HCV treatment initiations. For each province, the data were stratified in three birth cohorts: individuals born prior to 1945, individuals born between 1945 and 1965 and individuals born after 1965. We used a back‐calculation modelling approach to estimate prevalence and the undiagnosed proportion of CHC. The historical prevalence of CHC was inferred through a calibration process based on a Bayesian Markov chain Monte Carlo (MCMC) algorithm. The algorithm constructs the historical prevalence of CHC for each cohort by comparing the model‐generated outcomes of the annual incidence of the CHC‐related health events against the data set of observed diagnosed cases generated in the retrospective analysis.Results: The results show a decreasing trend in both CHC prevalence and undiagnosed proportion in BC, Ontario and Quebec. In 2018, CHC prevalence was estimated to be 1.23% (95% CI: .96%–1.62%), .91% (95% CI: .82%–1.04%) and .57% (95% CI: .51%–.64%) in BC, Ontario and Quebec respectively. The CHC undiagnosed proportion was assessed to be 35.44% (95% CI: 27.07%–45.83%), 34.28% (95% CI: 26.74%–41.62%) and 46.32% (95% CI: 37.85%–52.80%) in BC, Ontario and Quebec, respectively, in 2018. Also, since the introduction of new DAA treatment in 2014, CHC prevalence decreased from 1.39% to 1.23%, .97% to .91% and .65% to .57% in BC, Ontario and Quebec respectively. Similarly, the CHC undiagnosed proportion decreased from 38.78% to 35.44%, 38.70% to 34.28% and 47.54% to 46.32% in BC, Ontario and Quebec, respectively, from 2014 to 2018.Conclusions: We estimated that the CHC prevalence and undiagnosed proportion have declined for all three provinces since the new DAA treatment has been approved in 2014. Yet, our findings show that a significant proportion of HCV cases remain undiagnosed across all provinces highlighting the need to increase investment in screening. Our findings provide essential evidence to guide decisions about current and future HCV strategies and help achieve the WHO goal of eliminating hepatitis C in Canada by 2030.


  • Open Access

    Engagement with the HCV care cascade among high-risk groups: A population-based study

    by Aysegul Erman, Karl Everett, William W.L. Wong, Farinaz Forouzannia, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, Beate Sander

    Background: HCV elimination requires a thorough understanding of the care cascade. A direct-acting antiviral (DAA)-era description of the care cascade has not been undertaken in Ontario, Canada’s most populous jurisdiction. Our primary objective was to describe the current population-level care cascade in the general Ontario population and among key risk groups ─ baby boomers, immigrants, and individuals experiencing residential instability. The secondary objective was to identify predictors of engagement. Methods: We conducted a population-based cohort study of Ontario residents undergoing HCV testing between January 1, 1999, and December 31, 2018, and mapped the care cascade [antibody-diagnosed, RNA tested, RNA positive, genotyped, treated, achieved sustained virologic response, reinfected/relapsed] as of December 31, 2018. The cascade was stratified by risk groups. Cause-specific hazard modeling was used to identify demographic, and socioeconomic predictors of engagement with key steps of the cascade. Results: Among 108,428 Ontario residents living with an HCV antibody diagnosis, 88% received confirmatory RNA testing; of these, 62% tested positive and 94% of positive tests were genotyped. Of those with confirmed viremia, 53% initiated treatment and 76% of treated individuals achieved sustained virologic response, while ~1% experienced reinfection or relapse. Males, older birth cohorts, long-term residents, those with a history of substance use disorder and social marginalization (eg, material deprivation, residential instability), and those initially diagnosed in the pre-DAA era exhibited lower rates of engagement with almost every step of HCV care. Conclusions: Despite DAA era improvements, treatment initiation remains a major gap. HCV screening and linkage-to-treatment, particularly for those with a history of substance use disorder and social marginalization, will be needed to equitably close gaps in HCV care in the province.


  • Open Access

    Engagement with the HCV care cascade among high-risk groups: a population-based study

    by Aysegul Erman, Karl Everett, William W. L. Wong, Farinaz Forouzannia, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, Beate Sander

    Background Hepatitis C virus (HCV) elimination requires a thorough understanding of the care cascade. A direct-acting-antiviral (DAA)-era description of the care cascade has not been undertaken in Ontario, Canada. Our primary objective was to describe the current population-level care cascade in the general Ontario population and among key risk-groups — baby-boomers, immigrants, and individuals experiencing residential instability. The secondary objective was to identify predictors of engagement. Methods We conducted a population-based cohort study of Ontario residents undergoing HCV testing between January 1, 1999, and December 31, 2018, and mapped the care cascade [antibody diagnosed, RNA tested, RNA positive, genotyped, treated, achieved sustained virologic response (SVR), reinfected/relapsed] as of December 31, 2018. The cascade was stratified by risk groups. Cause-specific hazard modeling was used to identify demographic, and socioeconomic predictors of engagement with key steps of the cascade. Results Among 108,428 Ontario resident living with an HCV antibody diagnosis, 88% received confirmatory RNA testing; of these, 62% tested positive and 94% of positive tests were genotyped. Of those with confirmed viremia, 53% initiated treatment and 76% of treated individuals achieved SVR, while ∼1% experienced reinfection or relapse. Males, older birth cohorts, long-term residents, those with a history of substance use disorder and social marginalisation (e.g., material deprivation, residential instability), and those initially diagnosed in the pre-DAA era exhibited lower rates of engagement with almost every step of HCV care. Conclusions Despite DAA-era improvements, treatment initiation remains a major gap. HCV screening and linkage-to-treatment, particularly for those with a history of substance use disorder and social marginalisation, will be needed to equitably close gaps in HCV care in Ontario.

  • Open Access

    Effect of sustained viral clearance on liver-related mortality among individuals living with hepatitis C by treatment era: a population-based retrospective cohort study

    by Aysegul Erman, Karl Everett, William W. L. Wong, Farinaz Forouzannia, Christina Greenaway, Naveed Janjua, Jeffrey C. Kwong, Beate Sander

    Background Chronic infection with hepatitis C virus (HCV) is a leading cause of liver-related mortality. Direct-acting antivirals (DAAs) have revolutionised treatment by offering profound improvements in sustained viral clearance (SVR) and tolerability resulting in rapid expansion of treatment for individuals for whom HCV treatment had previously been less feasible, such as those with advanced liver disease or with drug and/or alcohol-related substance use. Given these clinical policy shifts, the primary objective of this study was to assess the impact of SVR on liver-related death among important clinical groups and the secondary objective was to explore changes in predictors of liver-related death by treatment era using real-world data from a large population-based cohort. Methods We conducted a population-based, linked cohort study of all Ontario residents with HCV viremia between January 1st, 1999, and December 31st, 2018, with follow up to 31st May 2021 (N=73,411). Population-level health administrative, clinical, and demographic data were accessed at ICES. Cause-specific hazard models were used to explore the impact of SVR on liver-related death and to identify factors associated with the rate of liver-related death in the DAA and pre-DAA treatment eras. The moderating effects of liver disease severity and substance-use disorder on the relationship between SVR and liver-related-mortality was explored by stratification. Results Among Ontario residents diagnosed with living with HCV, the achievement of SVR was associated with a significant reduction in liver related mortality (adjusted hazard ratio [aHR] 0.22, 95%CI: 0.20-0.24 vs. no SVR). This was also observed across progressive liver disease severity levels (aHR 0.13, 95%CI: 0.10-0.17 for individuals without cirrhosis; aHR 0.11, 95%CI: 0.06-0.17 for those with compensated cirrhosis, and aHR 0.24, 95%CI: 0.22-0.27 for those with advanced liver disease vs. no SVR) and by substance use status (aHR 0.24, 95%CI: 0.21-0.27 for those with a history of substance use disorder; and aHR 0.21, 95%CI: 0.18-0.24 for those without vs. no SVR). Additionally, factors such as age at diagnosis, sex, liver disease severity, immigration status, birth year, substance use, HBV-coinfection, viral genotype, and markers of social marginalisation were independent predictors of liver-related mortality. However, sex, and viral genotype no longer displayed significant associations with liver-related death in the DAA era as was observed in the earlier treatment era. Conclusions This study provides real-world evidence showing profound impact of SVR on liver-related mortality in a population-based sample of individuals with CHC and highlights the importance of early diagnosis and treatment. This study further demonstrates significant mortality benefits of SVR regardless of substance use status highlighting the importance of supporting marginalised individuals in treatment access.